Literature DB >> 19443656

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

Patrick J Hanley1, Conrad Russell Young Cruz, Barbara Savoldo, Ann M Leen, Maja Stanojevic, Mariam Khalil, William Decker, Jeffrey J Molldrem, Hao Liu, Adrian P Gee, Cliona M Rooney, Helen E Heslop, Gianpietro Dotti, Malcolm K Brenner, Elizabeth J Shpall, Catherine M Bollard.   

Abstract

The naive phenotype of cord blood (CB) T cells may reduce graft-versus-host disease after umbilical cord blood transplantation, but this naivety and their low absolute numbers also delays immune reconstitution, producing higher infection-related mortality that is predominantly related to CMV, adenovirus (Adv), and EBV. Adoptive immunotherapy with peripheral blood-derived virus-specific cytotoxic T lymphocytes (CTLs) can effectively prevent viral disease after conventional stem cell transplantation, and we now describe the generation of single cultures of CTLs from CB that are specific for multiple viruses. Using EBV-infected B cells transduced with a clinical-grade Ad5f35CMVpp65 adenoviral vector as sources of EBV, Adv, and CMV antigens, we expanded virus-specific T cells even from CB T cells with a naive phenotype. After expansion, each CTL culture contained both CD8(+) and CD4(+) T-cell subsets, predominantly of effector memory phenotype. Each CTL culture also had HLA-restricted virus-specific cytotoxic effector function against EBV, CMV, and Adv targets. The CB CTLs recognized multiple viral epitopes, including CD4-restricted Adv-hexon epitopes and immunosubdominant CD4- and CD8-restricted CMVpp65 epitopes. Notwithstanding their naive phenotype, it is therefore possible to generate trivirus-specific CTLs in a single culture of CB, which may be of value to prevent or treat viral disease in CB transplant recipients. This study is registered at www.clinicaltrials.gov as NCT00078533.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443656      PMCID: PMC2738578          DOI: 10.1182/blood-2009-03-213256

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing.

Authors:  Krishna V Komanduri; Lisa S St John; Marcos de Lima; John McMannis; Steven Rosinski; Ian McNiece; Susan G Bryan; Indreshpal Kaur; Sean Martin; Eric D Wieder; Laura Worth; Laurence J N Cooper; Demetrios Petropoulos; Jeffrey J Molldrem; Richard E Champlin; Elizabeth J Shpall
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

2.  Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients.

Authors:  J Kurtzberg; M Laughlin; M L Graham; C Smith; J F Olson; E C Halperin; G Ciocci; C Carrier; C E Stevens; P Rubinstein
Journal:  N Engl J Med       Date:  1996-07-18       Impact factor: 91.245

3.  Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.

Authors:  Kenneth Micklethwaite; Anna Hansen; Aaron Foster; Elizabeth Snape; Vicki Antonenas; Mary Sartor; Peter Shaw; Ken Bradstock; David Gottlieb
Journal:  Biol Blood Marrow Transplant       Date:  2007-04-06       Impact factor: 5.742

4.  De novo T-lymphocyte responses against baculovirus-derived recombinant influenzavirus hemagglutinin generated by a naive umbilical cord blood model of dendritic cell vaccination.

Authors:  Amar Safdar; William K Decker; Sufang Li; Dongxia Xing; Simon N Robinson; Hong Yang; David Steiner; Gilhen Rodriguez; Elizabeth J Shpall; Catherine Bollard
Journal:  Vaccine       Date:  2009-02-06       Impact factor: 3.641

5.  Comparison of CD8+ T Cell responses to cytomegalovirus between human fetuses and their transmitter mothers.

Authors:  Beatrice Pedron; Valerie Guerin; Francois Jacquemard; Aline Munier; Fernand Daffos; Philippe Thulliez; Yannick Aujard; Dominique Luton; Ghislaine Sterkers
Journal:  J Infect Dis       Date:  2007-08-29       Impact factor: 5.226

6.  Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.

Authors:  Concetta Quintarelli; Gianpietro Dotti; Biagio De Angelis; Valentina Hoyos; Martha Mims; Luigia Luciano; Helen E Heslop; Cliona M Rooney; Fabrizio Pane; Barbara Savoldo
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

7.  Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.

Authors:  Ann M Leen; Anne Christin; Mariam Khalil; Heidi Weiss; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

8.  Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients.

Authors:  Tomoko Matsumura; Hiroto Narimatsu; Masahiro Kami; Koichiro Yuji; Eiji Kusumi; Akiko Hori; Naoko Murashige; Yuji Tanaka; Kazuhiro Masuoka; Atsushi Wake; Shigesaburo Miyakoshi; Yoshinobu Kanda; Shuichi Taniguchi
Journal:  Biol Blood Marrow Transplant       Date:  2007-02-28       Impact factor: 5.742

9.  Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources.

Authors:  Christopher M Walker; Jo-Anne H van Burik; Todd E De For; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2007-09       Impact factor: 5.742

10.  Rapid CD8+ T cell repertoire focusing and selection of high-affinity clones into memory following primary infection with a persistent human virus: human cytomegalovirus.

Authors:  Elizabeth K Day; Andrew J Carmichael; Ineke J M ten Berge; Edward C P Waller; J G Patrick Sissons; Mark R Wills
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

View more
  92 in total

1.  Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy.

Authors:  Sharon Lam; Julia Sung; Conrad Cruz; Paul Castillo-Caro; Minhtran Ngo; Carolina Garrido; Joann Kuruc; Nancie Archin; Cliona Rooney; David Margolis; Catherine Bollard
Journal:  Mol Ther       Date:  2014-11-04       Impact factor: 11.454

Review 2.  Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy.

Authors:  Deborah M Brown
Journal:  Cell Immunol       Date:  2010-02-24       Impact factor: 4.868

3.  Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

Authors:  Christian S Hinrichs; Zachary A Borman; Luca Gattinoni; Zhiya Yu; William R Burns; Jianping Huang; Christopher A Klebanoff; Laura A Johnson; Sid P Kerkar; Shicheng Yang; Pawel Muranski; Douglas C Palmer; Christopher D Scott; Richard A Morgan; Paul F Robbins; Steven A Rosenberg; Nicholas P Restifo
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

4.  Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus.

Authors:  Patrick J Hanley; Sharon Lam; Elizabeth J Shpall; Catherine M Bollard
Journal:  J Vis Exp       Date:  2012-05-07       Impact factor: 1.355

5.  Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.

Authors:  Gerrit Weber; Ignazio Caruana; Rayne H Rouce; A John Barrett; Ulrike Gerdemann; Ann M Leen; Karen R Rabin; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2013-07-09       Impact factor: 12.531

6.  Impact of T cell selection methods in the success of clinical adoptive immunotherapy.

Authors:  Natalia Ramírez; Lorea Beloki; Miriam Ciaúrriz; Mercedes Rodríguez-Calvillo; David Escors; Cristina Mansilla; Eva Bandrés; Eduardo Olavarría
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

7.  Low rate of infusional toxicity after expanded cord blood transplantation.

Authors:  Adham S Bear; Patrick J Hanley; Doyle M Bosque; Conrad R Cruz; Indresh Kaur; Hao Liu; Partow Kebriaei; Chitra Hosing; Katayoun Rezvani; Betul Oran; Marcos J De Lima; Catherine M Bollard; Elizabeth J Shpall
Journal:  Cytotherapy       Date:  2014-02-28       Impact factor: 5.414

8.  HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths.

Authors:  Shabnum Patel; Elizabeth Chorvinsky; Shuroug Albihani; Conrad Russell Cruz; R Brad Jones; Elizabeth J Shpall; David M Margolis; Richard F Ambinder; Catherine M Bollard
Journal:  Mol Ther       Date:  2018-04-12       Impact factor: 11.454

9.  Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution.

Authors:  Yeon Joo Lee; Dick Chung; Kun Xiao; Esperanza B Papadopoulos; Juliet N Barker; Trudy N Small; Sergio A Giralt; Junting Zheng; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-22       Impact factor: 5.742

10.  Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.

Authors:  G Weber; U Gerdemann; I Caruana; B Savoldo; N F Hensel; K R Rabin; E J Shpall; J J Melenhorst; A M Leen; A J Barrett; C M Bollard
Journal:  Leukemia       Date:  2013-03-01       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.